Cargando…

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy

Renal cell carcinoma (RCC) is the fourteenth most common cancer worldwide. In about 55% of cases, it is diagnosed at a localised and/or locally advanced stage and therefore amenable to a curative approach. Although nephrectomy still represents the cornerstone of non-metastatic RCC (nmRCC) treatment,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bottiglieri, Achille, Sepe, Pierangela, Stellato, Marco, Pircher, Chiara, Fotia, Giuseppe, Leone, Alberto Giovanni, Guadalupi, Valentina, Claps, Melanie, Giannatempo, Patrizia, Verzoni, Elena, Procopio, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584769/ https://www.ncbi.nlm.nih.gov/pubmed/36275783 http://dx.doi.org/10.2147/CMAR.S360441

Ejemplares similares

Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2021)

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
por: Raimondi, Alessandra, et al.
Publicado: (2020)

Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?
por: Mennitto, Alessia, et al.
Publicado: (2020)

The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
por: Raimondi, Alessandra, et al.
Publicado: (2019)

BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2022)

Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience
por: Sepe, Pierangela, et al.
Publicado: (2019)

Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression
por: Cappelletti, Vera, et al.
Publicado: (2020)

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
por: Procopio, Giuseppe, et al.
Publicado: (2022)

Integrative Transcriptomic Analysis Reveals Distinctive Molecular Traits and Novel Subtypes of Collecting Duct Carcinoma
por: Gargiuli, Chiara, et al.
Publicado: (2021)

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2020)

1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic
por: Claps, M., et al.
Publicado: (2021)

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators
por: Stellato, Marco, et al.
Publicado: (2021)

Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
por: Stellato, Marco, et al.
Publicado: (2021)

Second-line treatment in renal cell carcinoma: clinical experience and decision making
por: Guadalupi, Valentina, et al.
Publicado: (2021)

Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
por: Grassi, Paolo, et al.
Publicado: (2016)

Malignant Fibrous Histiocytoma of the Kidney Treated with Nephrectomy and Adjuvant Radiotherapy: A Case Report
por: Marchese, Rita, et al.
Publicado: (2010)

Predicting Molecular Models: Where Are We Going?
por: Ratta, Raffaele, et al.
Publicado: (2015)

Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2022)

Response to Targeted Therapy in Urachal Adenocarcinoma
por: Testa, Isabella, et al.
Publicado: (2014)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
por: Grassi, Paolo, et al.
Publicado: (2016)

PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
por: Franza, A., et al.
Publicado: (2021)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014)

Valorization of Olive Mill Byproducts: Recovery of Biophenol Compounds and Application in Animal Feed
por: Cifuni, Giulia Francesca, et al.
Publicado: (2023)

Referral and adjuvant treatment patterns after nephrectomy in high‐risk locoregional renal cell carcinoma
por: Dzimitrowicz, Hannah, et al.
Publicado: (2021)

Local Small Ruminant Grazing in the Monti Foy Area (Italy): The Relationship Between Grassland Biodiversity Maintenance and Added-Value Dairy Products
por: Claps, Salvatore, et al.
Publicado: (2020)

Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
por: Rizzo, Mimma, et al.
Publicado: (2021)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017)

Radical or simple nephrectomy in localized renal cell carcinoma: what is a choice?
por: Shulyak, Alexander, et al.
Publicado: (2011)

Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines
por: Savelkoul, Huub F. J., et al.
Publicado: (2015)

Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy
por: Leone, Andrew, et al.
Publicado: (2016)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy
por: Nicolai, Nicola, et al.
Publicado: (2022)

M tuberculosis in the Adjuvant Modulates Time of Appearance of CNS-Specific Effector T Cells in the Spleen through a Polymorphic Site of TLR2
por: Nicolò, Chiara, et al.
Publicado: (2013)

Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?
por: Maltoni, Roberta, et al.
Publicado: (2021)

Influence of Operator's Experience on the Shaping Ability of Protaper Universal and Waveone Systems: A Comparative Study on Simulated Root Canals
por: Troiano, Giuseppe, et al.
Publicado: (2016)

Laparoscopic retroperitoneoscopic nephrectomy and partial nephrectomy in children
por: Al-hazmi, Hamdan H., et al.
Publicado: (2015)

The Learning Curve for Radical Nephrectomy for Kidney Cancer: Implications for Surgical Training
por: Larcher, Alessandro, et al.
Publicado: (2023)

Patient Preferences in Adjuvant and Palliative Treatment of Advanced Melanoma: A Discrete Choice Experiment
por: WEILANDT, Juliane, et al.
Publicado: (2020)

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
por: Procopio, G, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4bo8ulu6ve9c7vhe6alck33dtc